Two-way evidence map

Start with an ingredient. Or start with the question.

Look up what has actually been studied, where the signal comes from, and where the evidence stops. Plant profiles also show which species and preparation the research means. Connections are research leads, not a list of treatments to take.

Showing 27 ingredients and 33 health topics.

Ingredient first

What has this ingredient been connected to?

Reviewed records available

Ashwagandha

Withania somnifera

The human evidence is more interesting than a simple yes or no. Five small sleep trials produced a favorable pooled signal. A separate stress review found lower cortisol but no statistically significant improvement in perceived stress.

Evidence review in progress

Black cohosh

Actaea racemosa

The evidence is not one tidy answer. A newer review reported improvement in some menopausal symptoms, while an earlier Cochrane review found no significant advantage for hot-flush frequency or overall symptom scores. We are keeping both visible while overlap and product differences are checked.

Reviewed records available

Broadleaf plantain

Plantago major

Broadleaf plantain is the common lawn and path-side plant Plantago major, not the banana-like food crop. The reviewed cards below concern specific standardized topical formulations used in clinical wound care. They do not establish that a fresh leaf, homemade poultice, seed preparation, or unspecified extract has the same effect.

Reviewed records available

Butterbur

Petasites hybridus

A named processed root extract showed a dose-specific migraine-prevention signal in one randomized trial. That result cannot be separated from butterbur's central safety boundary: the raw plant can contain toxic pyrrolizidine alkaloids.

Human evidence is limited

Chaga

Inonotus obliquus

Chaga has a large reputation and a much smaller human evidence base. The sources reviewed discuss laboratory and animal findings, but we did not identify convincing human clinical efficacy evidence for treating a health condition.

Reviewed records available

Cranberry

Vaccinium macrocarpon

Cranberry is a good test of whether an evidence page can resist a slogan. A large review found a preventive signal for women with recurrent UTIs, but not for every population. It studied prevention with juices, tablets, capsules, and powders, not treatment of an infection that is already present.

No compelling evidence identified

Dandelion

Taraxacum officinale

Dandelion has a long history of food and traditional use, but human research is sparse. NCCIH says there is no compelling scientific evidence supporting dandelion for any health condition.

Evidence review in progress

Elderberry

Sambucus nigra

A small clinical literature has examined short-term processed elderberry products after respiratory symptoms begin. That does not establish prevention, a general immune boost, or a treatment for COVID-19.

Traditional-use evidence only

European goldenrod

Solidago virgaurea

Goldenrod is a common name shared by many species. This profile is only for European goldenrod, Solidago virgaurea. The European Medicines Agency has a traditional-use monograph for its dried flowering parts; that regulatory history is not the same as convincing clinical evidence.

Evidence review in progress

Feverfew

Tanacetum parthenium

Feverfew has been studied for migraine prevention, but the trials are small and use different plants, preparations, and amounts. The mixed evidence is more useful than a blanket works-or-doesn't label.

Reviewed records available

Garlic

Allium sativum

Garlic can mean food, powder, aged extract, mouthwash, fresh topical use, or an isolated compound. Those are different exposures. The reviewed cards below cover aged-garlic preparations and garlic-based mouthwash without transferring those findings to ordinary food use, raw topical garlic, or systemic infection treatment.

Evidence review in progress

Ginger

Zingiber officinale

Ginger has a broad research literature, but the result depends on the problem being studied. Our first queue focuses on pregnancy-related nausea and keeps supplement trials separate from ginger used in food or tea.

Reviewed records available

Green tea

Camellia sinensis

A meta-analysis that pooled green tea drinks and extracts found a small average drop in LDL cholesterol and no significant change in HDL. Matcha is powdered whole leaf, but direct human evidence for matcha-specific health outcomes remains limited. Neither finding shows that green tea prevents heart attacks or strokes.

Evidence review in progress

Milk thistle

Silybum marianum

Milk thistle is heavily promoted for the liver, so the first queue starts with two rigorous silymarin trials that did not show the hoped-for benefit in their studied liver-disease settings. Those results are being reviewed before a detailed card is published.

Reviewed records available

Peppermint

Mentha × piperita

Peppermint tea and oral peppermint-oil products are different exposures. The reviewed evidence card covers oil formulations used in IBS trials. It found a symptom signal and more adverse events, while rating the evidence very low quality.

Reviewed records available

St. John's wort

Hypericum perforatum

Short trials found that some St. John's wort extracts had results similar to the SSRIs used as comparators for mild-to-moderate depression. The interaction problem is just as important as that signal: this plant can change how many medicines work.

Reviewed records available

Turmeric

Curcuma longa

A review of short knee-osteoarthritis trials found a pain signal for turmeric or curcumin products. The products were not one thing: culinary turmeric, concentrated curcuminoids, piperine combinations, and enhanced-absorption formulations should not be treated as equivalents.

Topic first

Which ingredients appear in research on this topic?

An appearance means a source record connects the ingredient and topic. The result may still be under review. It does not mean the ingredient works, is safe, or belongs in someone’s care plan.

The form matters

A plant name is not an intervention

Food, tea, fresh topical use, whole-plant powder, tincture, standardized extract, purified compound, and drug-grade product can have different doses, absorption, effects, and risks.

Every published connection should identify the studied preparation and route. When the source does not make that clear, the connection stays blocked rather than being generalized to every product with the same ingredient name.

  1. Food or ordinary culinary useWhat someone could reasonably eat.
  2. Whole plant or topical useLeaf, root, mushroom, tea, powder, or direct application.
  3. Extract or standardized productA defined preparation that may not match retail alternatives.
  4. Purified compound or medicineA molecule or drug-grade intervention, not evidence for the original plant as a whole.

How this stays manageable

AI does the repetitive work. Rules decide what can move.

AI can find sources, extract study details, normalize names, remove duplicates, and flag contradictions. Low-risk context from allowlisted sources can post automatically after exact source matching.

Benefit claims, dosage, interactions, pregnancy, serious disease, and safety signals still require review. Missing provenance is blocked, not queued.

Read the evidence method →